title: Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge.
abstract: Trypanosoma cruzi infects millions of people in Latin America and often leads to the development of Chagas disease. T. cruzi infection can be acquired at or near the bite site of the triatomine vector, but per os infection is also a well-documented mode of transmission, as evidenced by recent microepidemics of acute Chagas disease attributed to the consumption of parasite-contaminated foods and liquids. It would also be convenient to deliver vaccines for T. cruzi by the oral route, particularly live parasite vaccines intended for the immunization of reservoir hosts. For these reasons, we were interested in better understanding immunity to T. cruzi following oral infection or oral vaccination, knowing that the route of infection and site of antigen encounter can have substantial effects on the ensuing immune response. Here, we show that the route of infection does not alter the ability of T. cruzi to establish infection in muscle tissue nor does it impair the generation of a robust CD8(+) T cell response. Importantly, oral vaccination with attenuated parasites provides protection against wild-type (WT) T. cruzi challenge. These results strongly support the development of whole-organism-based vaccines targeting reservoir species as a means to alleviate the burden of Chagas disease in affected regions.
authors.affiliation: Department of Cellular Biology and Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA 30502, USA.
authors.forename: Matthew H
authors.initials: MH
authors.lastname: Collins
authors.forename: Julie M
authors.initials: JM
authors.lastname: Craft
authors.forename: Juan M
authors.initials: JM
authors.lastname: Bustamante
authors.forename: Rick L
authors.initials: RL
authors.lastname: Tarleton
mesh_terms: D000284:Administration, Oral; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D014355:Chagas Disease / Q000276:immunology / Q000517:prevention & control*; D056738:Cross Protection; D051379:Mice; D008810:Mice, Inbred C57BL; D009132:Muscles / Q000469:parasitology / Q000473:pathology; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014349:Trypanosoma cruzi / Q000276:immunology* / Q000472:pathogenicity; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology
chemical_list: D016052:Protozoan Vaccines; D014613:Vaccines, Attenuated